Publication: Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidate
Issued Date
2010-12-09
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-78649733251
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.5, No.11 (2010)
Suggested Citation
Jeffrey R. Currier, Viseth Ngauy, Mark S. de Souza, Silvia Ratto-Kim, Josephine H. Cox, Victoria R. Polonis, Patricia Earl, Bernard Moss, Sheila Peel, Bonnie Slike, Somchai Sriplienchan, Prasert Thongcharoen, Robert M. Paris, Merlin L. Robb, Jerome Kim, Nelson L. Michael, Mary A. Marovich Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidate. PLoS ONE. Vol.5, No.11 (2010). doi:10.1371/journal.pone.0013983 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28420
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidate
Abstract
Background: We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand. Methodology/Principal Findings: MVA-CMDR or placebo was administered intra-muscularly (IM; 107 or 108 pfu) or intradermally (ID; 106 or 107 pfu) at months 0, 1 and 3, to 48 healthy volunteers at low risk for HIV-1 infection. Twelve volunteers in each dosage group were randomized to receive MVA-CMDR or placebo (10:2). Volunteers were actively monitored for local and systemic reactogenicity and adverse events post vaccination. Cellular immunogenicity was assessed by a validated IFNγ Elispot assay, an intracellular cytokine staining assay, lymphocyte proliferation and a 51Cr-release assay. Humoral immunogenicity was assessed by ADCC for gp120 and binding antibody ELISAs for gp120 and p24. MVA-CMDR was safe and well tolerated with no vaccine related serious adverse events. Cell-mediated immune responses were: (i) moderate in magnitude (median IFNγ Elispot of 78 SFC/106 PBMC at 108 pfu IM), but high in response rate (70% 51Cr-release positive; 90% Elispot positive; 100% ICS positive, at 108 pfu IM); (ii) predominantly HIV Env-specific CD4+ T cells, with a high proliferative capacity and durable for at least 6 months (100% LPA response rate by the IM route); (iv) dose- and routedependent with 108 pfu IM being the most immunogenic treatment. Binding antibodies against gp120 and p24 were detectable in all vaccination groups with ADCC capacity detectable at the highest dose (40% positive at 108 pfu IM). Conclusions/Significance: MVA-CMDR delivered both intramuscularly and intradermally was safe, well-tolerated and elicited durable cell-mediated and humoral immune responses.
